Literature DB >> 15131401

BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.

Danièle Muller1, Catherine Bonaiti-Pellié, Joseph Abecassis, Dominique Stoppa-Lyonnet, Jean-Pierre Fricker.   

Abstract

OBJECTIVE: The purpose of this study was to determine whether two mutations detected frequently in a population of breast and/or ovarian cancer families originating from the northeastern part of France could be due to a founder effect.
METHODS: 83 index cases of families ascertained to have a familial breast and/or ovarian cancer history, were screened for mutations in all coding exons of the BRCA1 gene, using combined DGGE and direct sequencing. For haplotype analysis, six polymorphic markers were used for allelotyping of mutation carriers and non carriers from nine families with 3600del11 mutation and four families with G1710X mutation.
RESULTS: Of 83 index cases, 27 (32%) had 14 different BRCA1 mutations, one of which (G1710X), had not been reported in other populations. Two mutations were particularly common: 3600del11 in exon 11 accounted for 37% and the nonsense mutation G1710X in exon 18 for 15% of all mutations. We identified a common haplotype for each mutation suggesting a common founder for each recurrent mutation. No specific phenotype could be assigned to any of the common mutations.
CONCLUSIONS: These data demonstrate geographical clustering and suggest a founder effect for particular BRCA1 mutations, which identification will facilitate carrier detection in French families with breast cancer and breast and/or ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15131401     DOI: 10.1023/B:FAME.0000026819.44213.df

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  31 in total

1.  Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions.

Authors:  N Puget; D Stoppa-Lyonnet; O M Sinilnikova; S Pagès; H T Lynch; G M Lenoir; S Mazoyer
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

2.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

3.  A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.

Authors:  T Peelen; M van Vliet; A Petrij-Bosch; R Mieremet; C Szabo; A M van den Ouweland; F Hogervorst; R Brohet; M J Ligtenberg; E Teugels; R van der Luijt; A H van der Hout; J J Gille; G Pals; I Jedema; R Olmer; I van Leeuwen; B Newman; M Plandsoen; M van der Est; G Brink; S Hageman; P J Arts; M M Bakker; P Devilee
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

4.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

5.  A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes.

Authors:  S Thorlacius; G Olafsdottir; L Tryggvadottir; S Neuhausen; J G Jonasson; S V Tavtigian; H Tulinius; H M Ogmundsdottir; J E Eyfjörd
Journal:  Nat Genet       Date:  1996-05       Impact factor: 38.330

6.  Variation in BRCA1 cancer risks by mutation position.

Authors:  Deborah Thompson; Douglas Easton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-04       Impact factor: 4.254

7.  [Germ-line mutations of the BRCA1 gene in northeastern France].

Authors:  J P Fricker; D Muller; B Cutuli; J F Rodier; J C Janser; G M Jung; R Mors; T Petit; P Haegele; J Abecassis
Journal:  Bull Cancer       Date:  2000-10       Impact factor: 1.276

8.  Germline BRCA1 mutations in patients from 84 families with breast and/or ovarian cancers in northern France.

Authors:  J P Peyrat; P Vennin; L Hornez; J Fournier; C Adenis; J Bonneterre
Journal:  Eur J Cancer Prev       Date:  1998-02       Impact factor: 2.497

9.  Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.

Authors:  O Johannsson; E A Ostermeyer; S Håkansson; L S Friedman; U Johansson; G Sellberg; K Brøndum-Nielsen; V Sele; H Olsson; M C King; A Borg
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

10.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

View more
  14 in total

Review 1.  Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.

Authors:  H Wu; X Wu; Z Liang
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

2.  EGFR, BRCA1, BRCA2 and TP53 genetic profile in Moroccan triple negative breast cancer cases.

Authors:  Farah Jouali; Fatima Zahra El Ansari; Nabila Marchoudi; Amina Barakat; Hassaniya Zmaimita; Hamza Samlali; Jamal Fekkak
Journal:  Int J Mol Epidemiol Genet       Date:  2020-06-15

Review 3.  Mutations in context: implications of BRCA testing in diverse populations.

Authors:  Gabriela E S Felix; Yonglan Zheng; Olufunmilayo I Olopade
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

4.  Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?

Authors:  R El Tannouri; E Albuisson; P Jonveaux; E Luporsi
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

5.  A novel BRCA2 mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing.

Authors:  D Purnomosari; D K Paramita; T Aryandono; G Pals; P J van Diest
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

Review 6.  Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review.

Authors:  Carlos Andrés Ossa; Diana Torres
Journal:  Oncologist       Date:  2016-06-10

7.  Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population.

Authors:  Wijden Mahfoudh; Noureddine Bouaouina; Slim Ben Ahmed; Sallouha Gabbouj; Jingxuan Shan; Rebecca Mathew; Nancy Uhrhammer; Yves-Jean Bignon; Wafa Troudi; Amel Ben Ammar Elgaaied; Elham Hassen; Lotfi Chouchane
Journal:  Mol Biol Rep       Date:  2011-05-21       Impact factor: 2.316

8.  Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases.

Authors:  Sandrine Caputo; Louisa Benboudjema; Olga Sinilnikova; Etienne Rouleau; Christophe Béroud; Rosette Lidereau
Journal:  Nucleic Acids Res       Date:  2011-12-05       Impact factor: 16.971

Review 9.  A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.

Authors:  Fatemeh Karami; Parvin Mehdipour
Journal:  Biomed Res Int       Date:  2013-11-07       Impact factor: 3.411

10.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.